Discover
false
Paz Vellanki, MD, PhD
Former FDA oncology leader recognized for translating complex regulatory insight into actionable development strategy. Served as Associate Director in the FDA’s Division of Oncology 2, where she helped shape regulatory decisions and guide drug development across lung cancer, head and neck cancer, and rare tumors. Combines deep expertise in clinical trial design, INDs and drug applications with leadership in advancing novel endpoints, including serving as technical lead on FDA guidance for circulating tumor DNA (ctDNA) in early-stage solid tumors.
-
Read: Case Study: Global Phase 2 Drug Delivery in Advanced Colorectal Cancer
Case Study: Global Phase 2 Drug Delivery in Advanced Colorectal Cancer
-
Read: Case Study: Managing Complexity in an Autologous Cell Therapy Trial
Discover
-
Read: How Investigator Engagement Builds Enrollment Momentum
Discover
-
Read: Case Study: Nectin 4 Biomarker Testing for Oncology Clinical Programs
Discover
-
Read: Has the rest of the world finally caught up with Latin America?
Discover
-
Read: Case Study: Rapid Execution of Assay Validation Rescued Global Study
DiscoverTranslational Research - Assays
Case Study: Rapid Execution of Assay Validation Rescued Global Study
| -
Read: Clinical AI at Scale: Why Trust Matters More Than Speed
Discover
-
Read: Hidden Strategic Edge in Clinical Trials: Financial Project Management
Discover
-
Read: Why Most Early Autoimmune Trials Fail to Yield Decision-ready Evidence
DiscoverEarly Phase Research - Autoimmune
Why Most Early Autoimmune Trials Fail to Yield Decision-ready Evidence
|
Loading...
You've reach the end